JP2022533966A5 - - Google Patents
Info
- Publication number
- JP2022533966A5 JP2022533966A5 JP2021568390A JP2021568390A JP2022533966A5 JP 2022533966 A5 JP2022533966 A5 JP 2022533966A5 JP 2021568390 A JP2021568390 A JP 2021568390A JP 2021568390 A JP2021568390 A JP 2021568390A JP 2022533966 A5 JP2022533966 A5 JP 2022533966A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- pharmaceutical composition
- composition according
- approximately
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025117499A JP2025148491A (ja) | 2019-05-16 | 2025-07-11 | Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849068P | 2019-05-16 | 2019-05-16 | |
| US201962849072P | 2019-05-16 | 2019-05-16 | |
| US62/849,068 | 2019-05-16 | ||
| US62/849,072 | 2019-05-16 | ||
| EP19382425 | 2019-05-27 | ||
| EP19382424 | 2019-05-27 | ||
| EP19382425 | 2019-05-27 | ||
| EP19382424 | 2019-05-27 | ||
| PCT/IB2020/054655 WO2020230109A1 (en) | 2019-05-16 | 2020-05-16 | Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025117499A Division JP2025148491A (ja) | 2019-05-16 | 2025-07-11 | Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533966A JP2022533966A (ja) | 2022-07-27 |
| JP2022533966A5 true JP2022533966A5 (https=) | 2023-05-25 |
| JP7789563B2 JP7789563B2 (ja) | 2025-12-22 |
Family
ID=73288968
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568390A Active JP7789563B2 (ja) | 2019-05-16 | 2020-05-16 | Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療 |
| JP2025117499A Pending JP2025148491A (ja) | 2019-05-16 | 2025-07-11 | Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025117499A Pending JP2025148491A (ja) | 2019-05-16 | 2025-07-11 | Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20220233572A1 (https=) |
| EP (1) | EP3969011A1 (https=) |
| JP (2) | JP7789563B2 (https=) |
| CN (1) | CN113966220A (https=) |
| AU (1) | AU2020276703A1 (https=) |
| CA (2) | CA3140285A1 (https=) |
| WO (2) | WO2020230109A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12390172B2 (en) * | 2021-02-19 | 2025-08-19 | Canon Medical Systems Corporation | Method and apparatus for displaying medical images |
| WO2024064288A1 (en) * | 2022-09-22 | 2024-03-28 | Thomas Jefferson University | Tlr4 inhibitors for cancer treatment |
| IL321911A (en) | 2023-01-05 | 2025-09-01 | Merck Patent Gmbh | Aptol molecules for the treatment of ischemic stroke and intracranial hemorrhages |
| AU2024275027A1 (en) | 2023-05-22 | 2025-12-11 | Merck Patent Gmbh | New tlr-4 antagonist aptamers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JPH088933B2 (ja) * | 1987-07-10 | 1996-01-31 | 日本ゼオン株式会社 | カテ−テル |
| SG10201406016SA (en) | 2006-04-03 | 2014-11-27 | Stella Aps | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| ES2599979T3 (es) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
| EP2619189B1 (en) | 2010-09-24 | 2020-04-15 | Zoetis Services LLC | Isoxazoline oximes as antiparasitic agents |
| ES2555160B1 (es) | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
| WO2020069313A2 (en) * | 2018-09-28 | 2020-04-02 | Henry Ford Health System | Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke |
-
2020
- 2020-05-16 AU AU2020276703A patent/AU2020276703A1/en active Pending
- 2020-05-16 JP JP2021568390A patent/JP7789563B2/ja active Active
- 2020-05-16 CA CA3140285A patent/CA3140285A1/en active Pending
- 2020-05-16 US US17/611,497 patent/US20220233572A1/en active Pending
- 2020-05-16 WO PCT/IB2020/054655 patent/WO2020230109A1/en not_active Ceased
- 2020-05-16 CA CA3291318A patent/CA3291318A1/en active Pending
- 2020-05-16 US US17/611,500 patent/US20220233570A1/en active Pending
- 2020-05-16 CN CN202080044106.5A patent/CN113966220A/zh active Pending
- 2020-05-16 WO PCT/IB2020/054654 patent/WO2020230108A1/en not_active Ceased
- 2020-05-16 EP EP20728201.3A patent/EP3969011A1/en active Pending
-
2025
- 2025-07-11 JP JP2025117499A patent/JP2025148491A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533966A5 (https=) | ||
| Hod et al. | Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion. | |
| JP2023002662A5 (https=) | ||
| JP2023002544A5 (https=) | ||
| JPS60188323A (ja) | 心筋虚血治療用医薬組成物 | |
| JP2022517399A5 (https=) | ||
| US5869461A (en) | Reducing toxicity of L-nucleosides with D-nucleosides | |
| FI4285929T3 (fi) | Hbv:n yhdistelmähoito | |
| Schmidt et al. | Remote conditioning the heart overview: translatability and mechanism | |
| Ahmed et al. | Percutaneous closure of post-myocardial infarction ventricular septal defects: a single centre experience | |
| JP2023500182A5 (https=) | ||
| WO2019010484A2 (en) | SYNTHETIC BIOCONJUGATES | |
| IL179931A (en) | Use of a drug preparation drug to treat cardiovascular disease | |
| JP2013528649A5 (https=) | ||
| Mouas et al. | Embolization of multiple pulmonary arterial aneurysms in Behçet's disease | |
| JP2017521374A5 (https=) | ||
| de Gregorio et al. | Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease | |
| Muller et al. | Myocardial no-reflow treatment | |
| KR20120024572A (ko) | 대동맥 섬유증을 치료하기 위한 조성물 및 방법 | |
| Han et al. | Oncostatin M promotes infarct repair and improves cardiac function after myocardial infarction | |
| CN101448524A (zh) | 脑血管痉挛抑制剂 | |
| JP2022511673A5 (https=) | ||
| Kumar et al. | Endless journey of adenosine signaling in cardioprotective mechanism of conditioning techniques: clinical evidence | |
| JP2025513240A5 (https=) | ||
| JP2024520788A5 (https=) |